Английская Википедия:Firazorexton

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Infobox drug

Firazorexton (Шаблон:Abbrlink; development code TAK-994) is an experimental orexin 2 (OX2) receptor agonist first described in a 2019 patent filed by Takeda Pharmaceutical Company.[1][2]

Firazorexton was studied by Takeda for the treatment of narcolepsy.[3][4][5] It is a small-molecule and orally active compound and acts as a highly selective agonist of the orexin receptor 2 (OX2) with >700-fold selectivity over the orexin receptor 1 (OX1).[3][4][6][7] Firazorexton is related to danavorexton (TAK-925).[8] The compound reached phase 2 clinical trials for narcolepsy.[9] However, clinical development was discontinued in October 2021 for safety reasons.[8][10][11][12][13]

See also

References

Шаблон:Reflist

Шаблон:Orexin receptor modulators